-----BEGIN PGP PUBLIC KEY BLOCK-----
Version: GnuPG v1.4.12 (GNU/Linux)
mQINBFES3ZMBEADjIBApyo6hm1jU2fdyCYm99nSnutjaVfwQ8egnLa6FLSyJyl96
2lGfdwb9e5isH/Tujt7VFhmU7carTVz7rtJbaCqGcgLY6IUEy4VGakZCjw6vsPUQ
NJZN7vS9wG9gUsTrw0QhtC8IQ+TAvrIERi32zab5amdw/znpa8p/tiLjEFapd0wE
Lyr9txlpPl3T+64eZ35SfneHF0OYPS79qpK3KJt3TDCYFrM41EevLVzQRosTnygk
8lMvQfqtNkdRJpmNHsjG1kFOzoEINVTyY4PeO6rRaeDp6H2KD5tu9SXsi8uF1Ayt
F0fB+1c/WHTEvtvNneGonOkWWJokzayfMRvoDhxGsrFsASvoLZ21m7U9Fdyid4Cw
iU8pAgRCq53CV+YGLv6qioPDpuba0S4cO/eUPR6APcKHcE0xU5A5yIKiCPVQQKG3
85P4BRC+GwZ2ni2/cz/jwzFi/j9CuSoU3L1fLGN5wHmmMvNOSyIgtCWx7tnxvmGE
eGbLtwfgv8pXFF9WoH1d2nvZNdgWNaGrp1zxssho62pnO9FTe6FgvIyLD4v7OyIP
kPoTjWaaZh/U0hXeQyQOXKeTFEAMblMmpDHeCYLwjtWZLo4Z8+0Ez5sk3B0OETH4
B0K7hwIhIBqp9Gcgq4haSpo+vfxRJH3ouRGfbNMCcras1s+yBmUbvR3mBQARAQAB
tI9DYXRoYWwgR2FydmV5IChPdGhlciBhY2NzOiBvbmV0cnVlY2F0aGFsQHR3aXR0
ZXIsIGNhdGhhbGdhcnZleUBnaXRodWIsIGNhdGhhbGdhcnZleUBnaXRvcmlvdXMs
IGluZGllYmlvdGVjaC5jb20pIDxjYXRoYWxnYXJ2ZXlAY2F0aGFsZ2FydmV5Lm1l
PokCSwQTAQgANQIbAwULCQgHAwUVCgkICwUWAgMBAAIeAQIXgBAYMTI3LjAuMC4x
Ojk5OTk5BQJSeChBAhkBAAoJEL0iNgSYi5CZ3CwQAN3974eow6SnmAHdQY+Pq2La
l5YDRIqcrVO3ybDrZ0gscS9K3rqNN4VRY45RIeMaq+CVjIJYqLCOIkzFCxNCxiyp
ZjzRBOcEsH9j8sxRkUKLRSlTlb+u6SrQll16L5JLQY2tFl5dgpWgakQD7xD0iUQ4
qX/HEakQhGiCUypYKqrT5GgrIFVsf22OMxFbwflNO/QNwzZVBDxf2yqi/c40q/rZ
JGNUlqkh+vZ/8q38dTPdbehifaTQjx08T4iGt1H5qnDRM10y080YWlnd5R/EesjK
s+nDZzzkJnVgOdckPbSYBp1uWckbtF3RcyqN5Sy9Iq8Qi0oZllFWoWgkoaLaf6iS
cP2xQuVe69YjugU2jo+Q7ilQq3gg9fe4j7zLpKu8sUpCep2SJ65DbTyM/aUwBs7u
SyWvNMGiuQHU/2F6biVQpH4wzr02SheigPZ/XiXqhrBazvvfr1OcQe20zqapoW+5
mS/LVWApSoofckxzrWfCWZNaR2sdN7Pota/PiN8E3x67cepkG9wDld8Udah3zOmU
4HGaHhk5rSUgxgUklJIAwtAAuUfa91QS9QIAAsguBnhcZmQ57xNtxm1Hsc38ilul
FuRpu2wmBFCwh58ZTqksDi9A4TwtYTTV9c4rziggGq42dzoPUPOogvsi3bOA5jYg
L9ORLJzRvha6pwbjkeqoiQEcBBABCAAGBQJREt+1AAoJEGrLMO47PegIOQoH/2rq
xrjaXxl1s2U2X9GmvOZNJY24qx8vcbkAT8XLOYkEtnPBbSmGrZipD320RHDp1BWI
wBDpJ6sz6eDaV087GnBAFzbmiDhDaRyukaIIx+/CJcSGqU11kNLPQpfCtKTPLfDi
ObMkzHdu6PSAt0jkqGFgIOmMlk5Y+KVJdilIeCnnbPOjzkp5sjbSY0ao5MsLk5xy
KicmpfxkxXPXddQAzgK1Nj0SmTP1azl5J6ePaly1RZkNApF6uI/6nlrBoq4Ij4Mr
pVzWxK8iTtvA4/7VOuTZ+EAsBC7Vhn1gcaD63bmELu70RGCQn49pkcSAB36zMrr3
eeqbi41Yk5JZg3iUkWOJAjcEEwEIACEFAlES3ZMCGwMFCwkIBwMFFQoJCAsFFgID
AQACHgECF4AACgkQvSI2BJiLkJnoUg//efW/Oqka179pVrWoQHuOKBB6SwDCUpcZ
uXYor4TJXf3DRujFFWz3D+Id12WtvA7C1oSXzXiCm2AUlZdwVvVEgloDZOU5iYDI
7ZgtxlMNVBzNt6SrYVrzikpYk6mQu5F0shLaXMjfaW2SxHv9i2KhRkXdKzuQ+yu0
FAz4kZRfJXZ2CEocJlIWCru7pbHwHzvB64bNmVUikESoLa5ou5ulKnd0gNB9aQFV
wV9Tit1pUQXJUfY7PvND5QfkJRFaldb+Gy64lPEjrwzWs1irwv3kiQXIEes3tTIC
WIutVcJ8AM9J4ietIOZfHq1wdOIQBDopY8Kz9H/+RLzNWosYDnj0UbWnw2mV4PdM
B9fFP3TIIZsbjJ4s+Qm9HdBrsP5iJbjRUX0EzEwNsIvaCPGtBPsVgNtOHMp5ccMX
cCBOWG4ZwPjUDgNyFQ22rNWLJYp1ZGYcxa0o7xSEXarDPde6q4OfhcrPkMIuC3jN
fivA8LcaNwzeZL6BArtaAKFb8zLeig9BBxaRhOLECuVbe0ZwMvsCgshV9HOGqnrc
hD3mjaxIJ+Psr4FM0xU6dVBq/OMcGclRkO0bo+kCJ2qpCWpPAGyjiLYePxOU8eTK
6ag/ZGCxc03xMdMCS6OAMHY12Ap2J4sVdevn18Yb/Fok2P3NYwTK5Sv49iudR8Ac
Rjr7v+iQVEa0P0NhdGhhbCBHYXJ2ZXkgKE1pY3Jvc3RhdHVzIGFjY291bnQpIDxv
bmV0cnVlY2F0aGFsQHR3aXR0ZXIuY29tPokCNwQTAQgAIQUCUnf5wgIbAwULCQgH
AwUVCgkICwUWAgMBAAIeAQIXgAAKCRC9IjYEmIuQmVy1D/4g4ham77UexUomtYwl
8ID8rBC+4fnKQLU1nhhFybBAKxVx3LNZWf13LYBJPLU/TSHNMpeU4HnyobqLS3qn
X0FH/QlFx/PG1PZEYU8YWTsqfCiTS2lqECewe8tWjdgejUy8e168BJkKlbGycTSM
r00NcGVpfTMDVRyMX6/VO6U2HcP3Iyh1uJ9zi0zyCW8u4Ko7HpaG5WPHeytJAv/U
TtlhmEzGUgiDtMzIPsSYM57X43i3uwNHH7fPPyyThzDcF5BPSWorRXCOgspBm2OL
E+CGaE1aMV3ITNrpdMQ/qCWUAUocYBdbVMZ9RVbB6WhOJ+hzvQD/OkJEK4TogXN6
0P7dtdsnO77NmfsB7BewTfn09Z/o1fsfEbpiNyfYGqLDmtx4xurqL9FnnB5WYZEP
XlLPTELIM6N5HNu68FOd/4tvsMZm8TTpujvyMVsf2ummTzUx+ByWjDkfWN1bt1Oz
dzj0hfUg5f6RpuBQuYYchHHXpG5d3joXllag/0rO+cI3Sj5/Rep8n+OnsuOS8KN9
y4j9JB4uJvjvmuY6KJSjo4a+yNk2bGhIsLx/tz2yJCErh6odzQEjEqacH59qlgrm
7OPDG6YPUSVtKtGggIXmvNvF1K9znPyhZLQni9klkwpgv5dr1aKKQ495s5HsWvgi
VU746GG2dwqL/fyZpLccp3ypsLRLQ2F0aGFsIEdhcnZleSAoR2l0b3Jpb3VzIGNv
ZGUgaG9zdGluZyBhY2NvdW50KSA8Y2F0aGFsZ2FydmV5QGdpdG9yaW91cy5vcmc+
iQI3BBMBCAAhBQJSeCefAhsDBQsJCAcDBRUKCQgLBRYCAwEAAh4BAheAAAoJEL0i
NgSYi5CZD/EQAJfiV+HGGiNzkKL8O/iIJDtXitQ7cGtK0k7L5nAI+p9p/VI15wgc
Z3OaLPfau/rmv0th9i1DR2ACSdQ4Bvtsb9pUzFDZIdwWQiCs+zj77sKRA8a5x6Oi
Ye2o2hIG/oTMDT2lVMmg5xj2+oPZ2eR05HmUtTwXPyx0VIpIUwLdT9uGAOEgHiQH
xUJXDLShtWrEWsStiDrfGXEUrfnhJ0nJBrhTRtvjlSeSqbATE7inWLI9w4j3ry5x
jNJuYVfreYPH23oVBdeV72B5zmirzKGoYLS194eGrHS7p6F7XMRUY2TVBbOaEx2Q
LD+VrITT5A12JJqeDVlA/qUvYADHSTGN5b3cHL5fUPWylpi5Z//5ZHqSjNTdDqyq
7HR6eVp0xo9wmTDodLKN1eB8CM/ykGVAcUaiVTVlyOpsZPtVDIjTMS/+n9XVJdVs
iYttgWhU6riH+XvTmxYWF+EzLyWGzBXlqVwOUODIVEtPgZa7ysyOfG0/LEKGcN4w
XDOfOZMI27K4yd+HJ64ceaTSlHzYD24tf/S+zsy4Cul15I/wFyMgM9GnFFECMbV1
VdnInSRBV/ROmq30+d5InZJYxuIp6qAVo38O6kqTXSfShb+vkDpctb1orZ2lAghu
1M/Lp7NTL10MHtXkcgTYowmHRFzyRI1KvlfL0FbTEhwvM/d1Pxwwlh07uQINBFES
3ZMBEAC5Ij59GR6W6qlC6u5ZNMz50jkPll8ZLnr2dOec2luUk8/rvyJhuk5oo9zF
ZYzBUe5ghtXVPo5CRJqWMh9r3LsWN1wXA7l82sNCyygCeS2g8bKMrO+zXeFFgoT2
fbLcbZbmYFP45SB32s1R1Fe4ujTC7BNUlQ3tf5j7VlYUmQyGzWfSpkzpY33TN6xr
kJICIOiBkYxkbi8CwSxO/xrPwY2/+mDNHlnVrL92HNLorSf9dcwFkweSDcUcUuic
bMBEp4gRnXboNNmbAmATsPRadQhZsBhW9XHcEO/Xwy7DBh4V8S4/Xyu0c2jH3jAc
vv0oEmgYTua2IsNc2Gd8Y5E/h/NOUsszSTu0EY8NtdPVVc1BVxN4Yw7CgAeMTe8e
iArpFL9KqrD8Dl+dj9IQ3acapkTyozEyxbWOylBSIHhtfsL55z0AnBZfshO0pIN1
82oJbiVjZJvtHkvoCBrRAfxas9PP/ZaZdnB++pcaju9NFlyvlAzYM9tt4JzosBrv
K4adat9jCnddcda+AMiBt5tgVGuckOv2W6E4sN/r0MucXHOI4SOP0iD74XkZOcq5
SUiGnGXsEgeztFXqsxo7eZpZ9oE4C7TrGzb5izAGLbpd7SjY+05BPEkDqt7QesMb
V3jw5xMnIWphfhecOTcAo/gQGu4NT+mu6quI/RYablhCZ3gqNwARAQABiQIfBBgB
CAAJBQJREt2TAhsMAAoJEL0iNgSYi5CZDQ4P/RMg32j+dsUjs7WIFuJrUIKKbVBY
1jLA5VXMytWCMmqBYj7b3G6xhCgnGZXEjYBVUvzLmf0ZuH6hVHEVvCY6BVA05WHj
HQy2qebu9462XLkEnfglKlFl8KQMTjzkhpoLFscUYYyJ/oeKENodc4i8M8ninPUw
SbOqlyEhnkHtkgcLTokWkZ4P5D0l0njxH+oMvPHS/SYD0/BWPrkfAqkUK/jHzpKF
mvuohlpMxwJ3s/3za29Cu33SAHklTtV4QMLIyf+Z4qTbIQ6Ae/E7qryWK6iovvO9
vj6NARjvkZLrWy4t8PQNkHpc0rRX0kc13EV/J3/SHU2MPq3Quiz8Qwmu6DiyENWg
Nn0ewEl0UCgXt9f4JVzRrNXxzz/kRo3kaOwMTfHJemiJZNaV9/hWnReZYt/qxqht
7JoNEg5dKgXtCOnKtmEbzWVgbu34oMvMjcltSmnuCTwi65uIZJ1FW0aJjwfGssuj
XaAsEFDr1vEYmytKwixH8F4pst+NFIL+qcJmgv5ly8IFSpjl9wa339dnm2m/4v6e
TsxhlQU9cdHSt9/NAzfqasn8FN3xRtukBRzM3vUVCljqic3TlzrmfUjfK0X6ysm6
GS2Pw4m8UDcHv0UkGvfCNxTmPe7UC9sv4znhM3oDecewInMRoWy6LyB97bvqQhRn
ohzRIlrk1LdGFiPy
=wOG4
-----END PGP PUBLIC KEY BLOCK-----
-----BEGIN PGP SIGNATURE-----
Version: GnuPG v1.4.12 (GNU/Linux)
Comment: Using GnuPG with Thunderbird - http://www.enigmail.net/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=8xhk
-----END PGP SIGNATURE-----
"The trials appeared to have enough statistical similarity that they
could be combined."
ALARM ALARM ALARM
I discard most "metastudies" if they can't immediately convince me
they're not a fishing expedition. Do they have an entire paper chapter
devoted to "all the studies we didn't incorporate"?
When presented with a corpus of research data that you propose a
"metastudy" of, if you want a certain answer you can trivially (and
crucially *unconsciously*) choose just the studies that, by
statistically irrelevant chance variance, will present the answer you
want when considered in aggregate.
This method is used by unscrupulous drug manufacturers all the time; as
they are not required (yet) to release *all* of their trials for
assessment by the FDA etc., they instead release the fraction of their
trials that support their assertion of benefit, and withhold the others.
Say you want to prove your coin flip can cure cancer. Trivial; just
release the trial data where flipping heads lead to better patient
outcomes, and disregard the rest. Same for a "meta-analysis" of studies
examining coinflips which all get different results; you can
deliberately or inadvertently (due to confirmation bias) disqualify
studies that disagree with your hypothesis and get *great, solid*
statistical answers that support it.
On 22/02/14 00:43, David Murphy wrote:
>> What are the excipients
>
> this is the sort of criticism which could be applied to every trial ever
> for anything and leaves me thinking of a certain episode of "yes minister"
>
> *Sir* *Humphrey*: In stage two you go on to discredit the information
> you're not publishing.
> *Jim* *Hacker*: How, if you're not publishing it?
> *Sir* *Humphrey*: It's much easier if it's not published. You do it by
> press leaks. Say it leaves some important questions unanswered, that much
> of the evidence is inconclusive, that the figures are open to other
> interpretations, that certain findings are contradictory and that some of
> the main conclusions have been questioned.
> *Jim* *Hacker*: Suppose they haven't?
> *Sir* *Humphrey*: Then question them. Then they have.
> *Jim* *Hacker*: But to make accusations like that you'd have to go through
> it with a fine-toothed comb.
> *Sir* *Humphrey*: Nonsense - you can say all that without reading it. There
> are always some questions unanswered.
> *Jim* *Hacker*: Such as?
> *Sir* *Humphrey*: The ones that weren't asked.
>
> Lets just jump straight to the Cochrane Review
>
> http://summaries.cochrane.org/CD007176/antioxidant-supplements-for-prevention-of-mortality-in-healthy-participants-and-patients-with-various-diseases
>
> The present systematic review included *78 randomised clinical trials*. In
> total, 296,707 participants were randomised to antioxidant supplements
> (beta-carotene, vitamin A, vitamin C, vitamin E, and selenium) versus
> placebo or no intervention. Twenty-six trials included 215,900 healthy
> participants. Fifty-two trials included 80,807 participants with various
> diseases in a stable phase (including gastrointestinal, cardiovascular,
> neurological, ocular, dermatological, rheumatoid, renal, endocrinological,
> or unspecified diseases). A total of 21,484 of 183,749 participants (11.7%)
> randomised to antioxidant supplements and 11,479 of 112,958 participants
> (10.2%) randomised to placebo or no intervention died. The trials appeared
> to have enough statistical similarity that they could be combined. When all
> of the trials were combined, antioxidants may or may not have increased
> mortality depending on which statistical combination method was employed;
> the analysis that is typically used when similarity is present demonstrated
> that antioxidant use did slightly increase mortality (that is, the patients
> consuming the antioxidants were 1.03 times as likely to die as were the
> controls). When analyses were done to identify factors that were associated
> with this finding, the two factors identified were better methodology to
> prevent bias from being a factor in the trial (trials with 'low risk of
> bias') and the use of vitamin A. In fact, when the trials with low risks of
> bias were considered separately, the increased mortality was even more
> pronounced (1.04 times as likely to die as were the controls). The
> potential damage from vitamin A disappeared when only the low risks of bias
> trials were considered.
> *The increased risk of mortality was associated with beta-carotene and
> possibly vitamin E and vitamin A, but was not associated with the use of
> vitamin C or selenium. The current evidence does not support the use of
> antioxidant supplements in the general population or in patients with
> various diseases.*
>
>
> On Fri, Feb 21, 2014 at 4:01 PM, Jonathan BISSON
> <bjonnh-diybio@bjonnh.net>wrote:
>
>> David Murphy <murphy.david@gmail.com> writes:
>>
>>>> Really ? Do you have sources about that ?
>>>
>> http://www.goodreads.com/quotes/735647-two-large-trials-of-antioxidants-were-set-up-after-peto-s
>>> Two groups of people at high risk of lung cancer were studied: smokers,
>> and
>>> people who had been exposed to asbestos at work. Half were given
>> 3-carotene
>>> and vitamin A, while the other half got placebo. Eighteen thousand
>>> participants were due to be recruited throughout its course, and the
>>> intention was that they would be followed up for an average of six years;
>>> but in fact the trial was terminated early, because it was considered
>>> unethical to continue it. Why? The people having the antioxidant tablets
>>> were 46 per cent more likely to die from lung cancer, and 17 per cent
>> more
>>> likely to die of any cause,* than the people taking placebo pills.
>>>
>>> http://www.ncbi.nlm.nih.gov/pubmed/15572756
>>> The Beta-Carotene and Retinol Efficacy Trial (CARET) tested the effect of
>>> daily beta-carotene (30 mg) and retinyl palmitate (25,000 IU) on the
>>> incidence of lung cancer, other cancers, and death in 18,314 participants
>>> who were at high risk for lung cancer because of a history of smoking or
>>> asbestos exposure. CARET was stopped ahead of schedule in January 1996
>>> because participants who were randomly assigned to receive the active
>>> intervention were found to have a 28% increase in incidence of lung
>> cancer,
>>> a 17% increase in incidence of death and a higher rate of cardiovascular
>>> disease mortality compared with participants in the placebo group.
>>>
>>>
>> All of that is interesting but:
>> They are taking tablets so:
>> - What are the excipients
>> - What is the purity of the "antioxydants". Working in a phytochemistry
>> lab that is concerned by this question, I can tell you that the 99.9%
>> purity advertised is almost NEVER the case. And when you have a 95%
>> purity on 30mg of something, it's still 1.5mg of ... something ... which we
>> may hope it's water... Well it's not just that... And I don't talk about
>> mixtures of compounds advertised as a single compound because the
>> analytical technique used can't discriminate between them. It's like,
>> hey here is a nice mattress... Oh and I have 0.01% bed bugs inside it, but
>> it's nothing .01% tsss...
>> - What about the matrix effect ? Taking a pure compound from a dry
>> tablet is not the same matrix as taking it from food. The pH is not the
>> same, the sugar/lipids content is not the same (modifying
>> absorption/release in the gut... hey wait a minute...). And what about the
>> effect of the tablet on smokers ? You have all the previous elements,
>> someone smokes, where are the compounds and excipients ? still in his
>> mouth, in his gut ?
>>
>> --
>> -- You received this message because you are subscribed to the Google
>> Groups DIYbio group. To post to this group, send email to
>> diybio@googlegroups.com. To unsubscribe from this group, send email to
>> diybio+unsubscribe@googlegroups.com. For more options, visit this group
>> at https://groups.google.com/d/forum/diybio?hl=en
>> Learn more at www.diybio.org
>> ---
>> You received this message because you are subscribed to the Google Groups
>> "DIYbio" group.
>> To unsubscribe from this group and stop receiving emails from it, send an
>> email to diybio+unsubscribe@googlegroups.com.
>> To post to this group, send email to diybio@googlegroups.com.
>> Visit this group at http://groups.google.com/group/diybio.
>> To view this discussion on the web visit
>> https://groups.google.com/d/msgid/diybio/8738jc4fq9.fsf%40lappynou.i-did-not-set--mail-host-address--so-tickle-me
>> .
>> For more options, visit https://groups.google.com/groups/opt_out.
>>
>
--
Please help support my crowdfunding campaign, IndieBB: Currently at
26.4% of funding goal, with 20 days left:
http://igg.me/at/yourfirstgmo/x/4252296
T: @onetruecathal, @IndieBBDNA
P: +3538763663185
W: http://indiebiotech.com
Re: [DIYbio] Re: Antioxidant supplements are bad for you
5:08 PM |
Subscribe to:
Post Comments (Atom)






0 comments:
Post a Comment